Seasonal Influenza Vaccination in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib

are warranted to evaluate whether ibrutinib impairs or improves vaccine response relative to other treatments.Limitations of the study include a small sample size and incomplete laboratory confirmation of influenza infection.Furthermore, defining an appropriate control group may prove challenging; treatment-naive patients often have immune impairment related to their disease while patients in remission after chemoimmunotherapy may experience the immunosuppressive effects of treatment. 7Conclusions | Our data show that an antibody response to influenza vaccination is permissible in patients receiving singleagent ibrutinib.Up to 74% of patients achieved seroprotective titers against common influenza viruses after vaccination.Consequently, routine immunization against influenza should be considered in accordance with the Centers for Disease Control and Prevention recommendations for immunocompromised patients.